Apotex To Study Chromosomal Abnormalities With Ferriprox Postapproval
Executive Summary
Apotex will conduct a study evaluating lymphocyte clastogenicity in thalassemia patients switching to its Ferriprox (deferiprone) after receiving Novartis' Desferal (deferoxamine), the European Public Assessment Report for Ferriprox states.